Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 2962-2968

  Jorgensen, J H ^a   Weigel, L M ^a   Swenson, J M ^a   Whitney, C G ^a   Ferraro, M J ^a   Tenover, F C ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CLINAFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; EUROPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; STREPTOCOCCUS PNEUMONIAE;

EID: 0033734978     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.2962-2968.2000     Document Type: Article

References (29)

1. Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae
2. Community-acquired pneumonia in adults: Guidelines for management. Guideline from The Infectious Diseases Society of America
3. In vivo selection of Streptococcus pneumoniae resistant to quinolones, including sparfloxacin
4. Emergence of drug-resistant pneumococcal infections in the United States
5. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system
6. Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia
7. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
8. Antimicrobial resistance with Streptococcus pneumoniae in the United States
9. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
10. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
11. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae; Results of a 1992-1993 Western Europe and USA collaborative surveillance study
12. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
13. Results of the Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens
14. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
15. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
16. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
17. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
18. Will pneumococci put quinolones in their place?
19. Identification of multiple clones of extended-spectrum cephalosporin-resisrant Streptococcus pneumoniae isolates in the United States
20. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
21. Cloning and characterization of the parC and pare genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
22. Characterization of a mutation in the pare gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
23. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae
24. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
25. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
26. The fluoroquinolones